Introducing "Light the Way:” A new dawn in ALS care and support

Group 48096116-1

As we step into a new era of medical innovation, it's crucial to shine a light on diseases that have long remained in the shadows. Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease also known as motor neurone disease (MND), is one such condition that has challenged medical experts for decades. Today, we’re thrilled to share a beacon of hope in this challenging landscape: Sano’s launch of “Light the Way.”

ALS/MND, known for its rapid progression and severe impact on those it affects, has long needed a more comprehensive approach to care and support. “Light the Way” is our response to a crucial unmet need – the lack of consistent support for those at risk. This multifaceted program is dedicated to supporting individuals who carry genes associated with ALS/MND.

This pioneering initiative offers a comprehensive range of services, including genetic testing, education, counselling, and support, specifically tailored to those at genetic risk for ALS/MND. An integral part of this initiative is the Beacon study, an observational study that charts the psychological impact of ALS/MND genetic testing. This study is critical in understanding and developing new policies to support those at risk of genetic ALS/MND. “Light the Way” embodies the intersection of science and empathy, standing as a testament to what can be achieved when these two forces unite.

 

 

We’ve launched this program initially in the United States, and plan to introduce a Spanish language version and expand to the United Kingdom in early 2024. The ultimate vision is global, with a goal to extend the service to other languages and countries, reaching individuals who are often underserved by healthcare systems.

For those interested in learning more or getting involved with the “Light The Way” initiative, please visit: https://portal.sanogenetics.com/en-us/study/light-the-way.

Get in touch